NewcelX Ltd. (NCEL): Total Assets
$11.45M
As of 2025-12-31
+7.3%
3-year compound annual growth
+56.7%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $11.45M | n/m | 2026-04-29, Balance as of period end |
| 2024-12-31 | $903.0K | -51.1% | 2026-04-29, Balance as of period end |
| 2023-12-31 | $1.85M | -80.1% | 2025-05-16, Balance as of period end |
| 2022-12-31 | $9.28M | +60.9% | 2024-05-15, Balance as of period end |
| 2021-12-31 | $5.76M | +375.8% | 2023-05-05, Balance as of period end |
| 2020-12-31 | $1.21M | +74.0% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $696.4K | n/a | 2021-05-14, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| NewcelX Ltd. (NCEL) | 2025-12-31 | $11.45M | n/m |
| Curanex Pharmaceuticals Inc (CURX) | 2025-12-31 | $11.58M | n/m |
| Revelation Biosciences, Inc. (REVB) | 2025-12-31 | $11.58M | +74.9% |
| MetaVia Inc. (MTVA) | 2025-12-31 | $11.12M | -31.6% |
| Mira Pharmaceuticals, Inc. (MIRA) | 2025-12-31 | $11.09M | +279.5% |
| Decoy Therapeutics Inc. (DCOY) | 2025-12-31 | $11.06M | +265.8% |
| Lantern Pharma Inc. (LTRN) | 2025-12-31 | $11.04M | -56.8% |
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | $12.00M | +165.1% |
| Anebulo Pharmaceuticals, Inc. (ANEB) | 2025-06-30 | $12.15M | +198.2% |
Compare NCEL, CURX, REVB, MTVA side by side · Screen every company in Pharmaceutical Preparations ↗